© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Gefitinib stands out as a molecularly targeted therapy, classified within the larger group of tyrosine kinase inhibitors. People working in pharmaceuticals and medicine know it for its specific action on the epidermal growth factor receptor (EGFR), which plays a major role in the growth and survival of cancer cells, especially in certain lung cancers. Its use often reflects advancements in personalized therapy, moving away from blanket approaches towards more intentional, effective intervention at the molecular level.
Gefitinib takes on several physical forms depending on the requirements—from white to off-white crystalline powder, acknowledging varying purity and manufacturing nuances. Dry handling shows the substance as a fine, loose solid that can appear as small flakes, lending a smooth texture that differs from more granular chemical agents. Touching or observing bulk forms, you’ll notice a non-hygroscopic, low-odor profile, reducing the challenges often seen with volatile or highly reactive oncology drugs.
The molecular structure of Gefitinib is precise and crafted for function: C22H24ClFN4O3. The molecule features a core quinazoline scaffold, appended with anilide and morpholine groups, a fluoro-aniline substitution, and a chloro substituent. These components line up to create selective EGFR inhibition. Chemists recognize a molecular weight of 446.90 g/mol. Visualizing its atomic arrangement, one notices the density of active chemical groups positioned for optimal receptor interaction, which means targeted cell effects with less collateral chemical activity.
Many labs report a melting point range of 193–197°C. This particular melting window gives process chemists reliable cues during manufacturing and quality assessment. The density checks in at about 1.28 g/cm3, indicating a moderate pack per unit of volume. Gefitinib resists dissolution in water, revealing itself as nearly insoluble, yet it dissolves well in DMSO, methanol, and certain organic solvents. A logP value of approximately 2.5 aligns with expected uptake and distribution patterns in the body, supporting oral administration.
Routine international shipping and procurement refer to the HS Code 2934999099, classifying Gefitinib as an “other heterocyclic compound” under chemical raw materials. This helps track imports and exports and brings standardization across customs departments. Companies use this designation to ensure paperwork and shipment stay in order, avoiding regulatory hold-ups that otherwise delay supply chains.
Gefitinib comes as powder, crystalline solid, and sometimes as flakes or fine pearls, depending on how it’s crystallized and ground during production. People working in research and manufacturing gain confidence from its uniform white color, which signals purity and proper storage. Batches show a free-flowing nature, which allows for easier measurement and combination into finished drug forms.
Gefitinib falls under hazardous chemicals, with risk for irritation to the eyes, skin, and respiratory tract. Lab workers need proper gloves, masks, and eye protection when dealing with raw powder. Spills or accidental contact call for immediate clean-up protocols. Beyond handling risks, oral exposure at research levels shows toxicity, which underscores why only licensed professionals access bulk forms. Safety Data Sheets recommend storage at room temperature, away from moisture, and under inert conditions to ward off unwanted reactions. Waste and disposal must stick to controlled protocols to limit environmental release.
In the pharmaceutical sector, Gefitinib serves as an active raw material for anti-cancer medications, predominantly tablets. Formulators blend it with excipients to shape, bind, and protect the active ingredient, everyone aiming to keep chemical integrity intact up until patient delivery. Work on new formulations sometimes converts the powder into pellets, microgranules, or suspension forms, each with their own shelf-life considerations and regulatory requirements. Use in research circles opens roads for analog development, where scientists tweak structure to improve potency or reduce side effects.
Through years in pharmaceutical research, a clear connection appears between a compound’s physical state and its clinical reliability. Compact, pure crystals keep dosing stable. Poor solubility can slow drug release or lower how much enters the bloodstream. Consistent particle size means uniform tablets, which tackles patient-to-patient variation. Toxicity tests on bulk material keep handlers safe, so proper training and easy-to-follow guidelines make a difference in both lab safety and environmental protection. A keen eye on these factors helps the entire chain, from raw material sourcing up to patient care, stay predictable and safe.
Experience in both research and pharmaceutical manufacturing shows that detailed work on characterization pays off in smoother scaling-up, fewer recalls, and faster time-to-market. The choice of solvents, control over humidity, and packing material all change how stable, active, and pure Gefitinib remains from the factory floor to the hospital pharmacy. Avoiding batch contamination, keeping dust at bay, and training people in cleanroom procedures keep all parties safer. Investing in automation, real-time quality checks, and green disposal methods cuts down on exposure risk and heavy chemical waste. Progress in these areas means fewer disruptions, less cost spread to patients, and predictable performance in clinical use.
